IL17A and inflammatory bowel disease: Due to the reported onset of paradoxical events (IBD exacerbation) after the treatment of IBD with anti-IL-17 agents [103], caution is necessary for HS patients with an increased risk for IBD when initiating an anti-IL-17 treatment [102].